# EDGAR Filing Document

**Accession Number:** 0001598646
**File Stem:** 0000000000-25-011919
**Filing Date:** 2025-12
**Character Count:** 2197
**Document Hash:** be307608bcc6dee12e27b7d252cdf975
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-011919.hdr.sgml**: 20260227

**ACCESSION NUMBER**: 0000000000-25-011919

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251231

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Minerva Neurosciences, Inc.
- **CENTRAL INDEX KEY:** 0001598646
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 260784194
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-292410

**BUSINESS ADDRESS:**
- **STREET 1:** 1500 DISTRICT AVENUE
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
- **BUSINESS PHONE:** 617-600-7373

**MAIL ADDRESS:**
- **STREET 1:** 1500 DISTRICT AVENUE
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-25-330849

## Text-Extract

```

                                                           December 31, 2025

Remy Luthringer
Chief Executive Officer and Chairman of the Board of Directors
Minerva Neurosciences, Inc.
1500 District Avenue
Burlington, MA 01803

       Re: Minerva Neurosciences, Inc.
           Registration Statement on Form S-3
           Filed December 23, 2025
           File No. 333-292410
Dear Remy Luthringer:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Daniel Crawford at 202-551-7767 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Ryan Sansom, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._